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AbstrAct
Introduction: Mouse models of emphysema are important tools for testing different 
therapeutic strategies. The aim of this study was to develop a mouse model of 
emphysema induced by different doses of elastase in order to produce different 
degrees of severity. 
Methods: Thirty female mice (C57BL/6) were used in this study. Different doses of 
porcine pancreatic elastase were administered intratracheally once a week for four 
weeks, as follows: 0.1 U (n=8), 0.15 U (n=7), and 0.2 U (n=7). Control mice (n=8) 
received 50 microL of sterile saline solution intratracheally. Lung mechanics were 
analyzed by plethysmography. Mean linear intercept and volume fraction occupied 
by collagen and elastic fibers were determined. 
results: An increase in lung resistance was observed with 0.2 U of elastase [median 
(P-25-P75): 2.02 (1.67; 2.34) cmH2O.s/mL], as well as a decrease in tidal volume 
and minute ventilation. Peak expiratory flow increased significantly in the groups 
treated with 0.15 U and 0.2 U of elastase. Mean linear intercept was higher with 0.15 
U and 0.2 U of elastase, with destruction of alveolar walls [median (P-25-P75): 30.31 
(26.65-43.13) microm and 49.49 (31.67-57.71) microm respectively]. The volume 
fraction occupied by collagen and elastic fibers was lower in the group receiving 0.2 
U of elastase. 
conclusion: Four intratracheal instillations of 0.2 U of elastase once a week induced 
changes in lung function and histology, producing an experimental model of severe 
pulmonary emphysema, whereas 0.15 U resulted in only histological changes.
Keywords: Pulmonary emphysema; lung mechanics; pancreatic elastase
Pulmonary emphysema is a chronic obstructive pulmonary disease 
marked by persistent airflow limitation and histologically characterized by 
permanent enlargement of airspaces distal to the terminal bronchioles, 
accompanied by destruction of their walls, and without obvious fibrosis1,2. 
Decreased alveolar radial support affects the elastic recoil properties of the 
lung, leading to expiratory collapse of small airways and subsequent air 
trapping. A striking feature of the emphysematous lung is the exacerbation of 
communicant airflow between the surrounding alveolar sacs, a mechanism 
known as collateral ventilation3. It is estimated that 210 million people 
currently have chronic obstructive pulmonary disease worldwide. The World 
Health Organization predicts that by 2030 this disease will become the 
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third leading cause of death in the world, with an 
increase in health care costs in industrialized and 
developing countries1,2,4.
So far, there has been no effective therapy 
able to mitigate morphological damage, improving 
lung function and symptoms. Smoking cessation 
and pulmonary rehabilitation programs can be of 
some benefit; however, most patients in advanced 
stages of the disease have dyspnea with minimal 
effort and poor quality of life2,5-8. Experimental 
models have been developed in an attempt to 
enhance our understanding of the pathophysiology 
of emphysema and to test new therapies, including 
genetic models and experimental emphysema 
induced by smoke exposure or enzymes such as 
papain and elastase9. The use of multiple doses of 
elastase has the ability to rapidly induce panacinar 
emphysema10, but high doses of elastase have 
been associated with increased mortality in 
mice10,11. Moreover, response to different treatments 
depends on the degree of emphysema2. 
The aim of this study was to develop a mouse 
model of emphysema induced by different doses 
of elastase in order to produce different degrees of 
disease severity.
Methods
This study was approved by the Research Ethics 
Committee of the Hospital de Clínicas de Porto 
Alegre under protocol number 13-0086. All animals 
received humane care in compliance with Brazilian 
Law No. 11.794/2008, the Brazilian Guidelines 
for the Care and Use of Laboratory Animals, the 
Guidelines for the Euthanasia of Animals, and 
the Guide for the Care and Use of Laboratory 
Animals prepared by the U.S. National Academy 
of Sciences. The experiments were carried out in 
the Experimental Animal Unit of the Experimental 
Research Center of Hospital de Clínicas de Porto 
Alegre.
Thirty-one two-month old female C57BL/6 mice 
weighing between 17 and 20 g were used in this 
study. Animals were anesthetized with isoflurane 
(5% for induction and 2% for maintenance) and 
received 10 mg/kg of tramadol intraperitoneally. 
With the mouse in the supine position, the trachea 
was accessed through a longitudinal incision in the 
midline of the neck, and the anterior aspect was 
exposed. The middle third of the cervical trachea 
was punctured with an insulin syringe-needle for 
infusion of saline or diluted elastase. The skin 
incision was closed with 5-0 nylon suture. While 
the mouse was still under sedation, positioning 
maneuvers were performed for better distribution 
of elastase in the lungs.
The mice were randomly divided into the following 
groups: control (C) and elastase (E10, E15, E20). 
In the C group (n=8), sterile saline solution (0.9% 
NaCl; 50 µL) was instilled intratracheally (i.t.). In E 
groups, three different doses of porcine pancreatic 
elastase (Sigma-Aldrich, St. Louis, MO, USA) 
were diluted with 50 µL of 0.9% NaCl and instilled 
i.t., as follows: E10 (n=8): 0.1 U of elastase; E15 
(n=7): 0.15 U of elastase; and E20 (n=8): 0.2 U of 
elastase. Each mouse received one infusion per 
week for four weeks.
One week after the fourth i.t. instillation, mice 
were anesthetized with ketamine (100 mg/kg) 
and xylazine (10 mg/kg), intraperitoneally. Lung 
mechanics were analyzed by plethysmography 
using the FinePointe™ Series Resistance and 
Compliance system (Buxco, Wilmington, NC, 
USA). The system was calibrated for a maximum 
volume of 0.25 mL and air pressure of 40 cmH2O. 
Tracheotomy was performed and a cannula inserted 
into the trachea. Mice were then mechanically 
ventilated in volume-controlled mode with a 
respiratory rate of 140 breaths per minute (bpm) 
and a positive end-expiratory pressure (PEEP) of 
2 cmH2O. Airway measurements were recorded 
over a 3-minute period after a 5-minute acclimation 
period followed by saline nebulization.
At the end of the experiment, mice were 
euthanized with an overdose of the same 
anesthetic mixture. The lungs were inflated and the 
trachea was clamped at end-expiration. The right 
lung was removed and fixed in 10% formalin for 
histological analysis. The left lung was immediately 
cryopreserved in liquid nitrogen and stored at -80°C 
for further analysis.
Three-μm-thick slices were cut from the 
peripheral part of the right lung and analyzed for (a) 
alveolar diameter, (b) volume fraction occupied by 
collagen fibers, and (c) volume fraction occupied 
by elastic fibers.
To determine alveolar diameter, sections 
were stained with hematoxylin and eosin. An 
optical microscope with a high-resolution camera 
(Axioplan, Zeiss, Thornwood, NY, USA) was used 
for morphometric analysis, and digital images were 
obtained. Overlay images with the reticulum were 
obtained using the ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). The 
reticulum contained a reference system with 100 
points and 50 line segments arranged in parallel. 
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Subsequent quantitative analysis was performed 
by the point-counting technique12. 
For mean linear intercept (Lm) determination, the 
number of alveolar intercepts was counted across 
20 random fields per slide at 400x magnification, 
where Lm = Σ length of the line segments (1250 
μm) / number of intercepts. Collagen (Sirius Red) 
and elastic fibers (Orcein dye) were quantified in 
the alveolar septa across 10 random fields per slide 
at 400x magnification using the ImageJ software. 
The results were expressed as a percentage of the 
amount of collagen and elastic fibers per area (%).
Because the data were nonparametric, they 
were analyzed using the Kruskal-Wallis test 
followed by Dunn’s test. Nonparametric data were 
and expressed as median and interquartile range 
(25th-75th percentile). All tests were performed 
using the Statistical Package for the Social 
Sciences (SPSS) version 20.0. The significance 
level was set at p<0.05.
results
No mice died during anesthesia or surgical 
procedures. One mouse in the E20 group was 
excluded due to the development of pneumonia. 
Thus, a total of 30 mice were available for analysis, 
eight in the C group, eight in E10, seven in E15, 
and seven in E20.
Lm increased with higher doses of elastase 
(figure 1). Lm was higher in E15 and E20 groups 
when compared to control values (p=0.028 and 
p=0.001, respectively). There was no significant 
difference between controls and E10 mice. Lm 
was higher in the E20 group than in E10 group 
(p=0.017) (figure 2).
The volume fraction of elastic fibers reduced 
significantly in the E20 group compared to all 
other groups (p=0.020). There was a significant 
difference between E20 and E10 groups (p=0.026) 
(figure 3). The volume fraction of collagen fibers 
also decreased in E15 and E20 groups compared to 
the C group (p<0.0001 and p<0.0001, respectively) 
(figure 4).
Lung resistance (R) was higher in the E20 
group than in the E10 group (p=0.008) (figure 5). 
No differences were observed in dynamic lung 
compliance (Cdyn) (figure 6). Tidal volume (TV; 
p=0.021), minute ventilation (MV; p=0.013) and 
peak expiratory flow (PEF; p=0.000) showed a 
greater decrease in the E20 group compared to all 
other groups (figures 7 and 8).
Figure 1: Lung parenchyma in an elastase-induced mouse model of emphysema  
Micrographs showing samples stained with hematoxylin and eosin one week after the last instillation of 
elastase or saline, which were administrated once a week for four weeks; original magnification x200.
A – normal lung architecture in the control group; B – discrete alveolar enlargement in animals treated with 0.1 U of elastase; 
C – moderate bronchiolar changes in animals treated with 0.15 U of elastase; D – severe alveolar destruction in animals 
treated with 0.2 U of elastase. Arrows show areas of emphysema.
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Figure 2: Mean linear intercept (Lm).
Values are the median of 7-8 animals (25th-75th percentile). Statistically significant difference between: *C versus E20 
(p=0.001); **C versus E15 (p=0.028); ***E10 versus E20 (p=0.017). C – control group; E10 – 0.1 U of elastase once a week 
for four weeks; E15 – 0.15 U of elastase once a week for four weeks; E20 – 0.2 U of elastase once a week for four weeks.
Figure 3: Volume fraction of the lung occupied by elastic fibers.
Values are the median of 7-8 animals (25th-75th percentile). Statistically significant difference between: *E10 versus 
E20 (p=0.026). C – control group; E10 – 0.1 U of elastase once a week for four weeks; E15 – 0.15 U of elastase once 
a week for four weeks; E20 – 0.2 U of elastase once a week for four weeks. ο = outlier values.
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Figure 4: Volume fraction of the lung occupied by collagen fibers. 
Values are the median of 7-8 animals (25th-75th percentile). Statistically significant difference between: *C versus 
E20 (p<0.0001); **C versus E15 (p<0.0001). C – control group; E10 – 0.1 U of elastase once a week for four 
weeks; E15 – 0.15 U of elastase once a week for four weeks; E20 – 0.2 U of elastase once a week for four weeks.
Figure 5: Lung resistance (R). 
Values are the median of 7-8 animals (25th-75th percentile). Statistically significant difference between: *E10 
versus E20 (p=0.006). C – control group; E10 – 0.1 U of elastase once a week for four weeks; E15 – 0.15 U of 
elastase once a week for four weeks; E20 – 0.2 U of elastase once a week for four weeks. ο = outlier values..
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Figure 6: Dynamic lung compliance (Cdyn).  
Values are the median of 7-8 animals (25th-75th percentile). No statistically significant difference between groups was detected.  
C – control group; E10 – 0.1 U of elastase once a week for four weeks; E15 – 0.15 U of elastase once a week for four weeks;  
E20 – 0.2 U of elastase once a week for four weeks. ο = outlier values.
Figure 7:  Plethysmography.   
Values are the median of 7-8 animals (25th-75th percentile). A – tidal volume (TV). Statistically significant difference between: *E10 versus E20 (p=0.041). B 
– minute ventilation (MV). Statistically significant difference between: *E10 versus E20 (p=0.024). C – control group; E10 – 0.1 U of elastase once a week for 
four weeks; E15 – 0.15 U of elastase once a week for four weeks; E20 – 0.2 U of elastase once a week for four weeks. ο = outlier values.
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Figure 8: Peak expiratory flow (PEF). 
Values are the median of 7-8 animals (25th-75th percentile). Statistically significant difference between: *C versus E20 
(p<0.0001); **C versus E15 (p=0.032); ***E10 versus E20 (p=0.001). C – control group; E10 – 0.1 U of elastase once a 
week for four weeks; E15 – 0.15 U of elastase once a week for four weeks; E20 – 0.2 U of elastase once a week for four 
weeks. ο = outlier values.
dIscussIon 
In the present study, we developed models 
of different degrees of emphysema induced by 
different doses of elastase in mice. For this purpose, 
lung mechanics and histology were analyzed. The 
highest dose (0.2 U) resulted in changes in lung 
mechanics associated with elastolysis and alveolar 
hyperinflation. An elastase dose of 0.15 U resulted 
in histological changes, but with no significant 
changes in lung mechanics. The lowest dose 
(0.1 U) led to no significant morphofunctional 
changes. 
Induction of emphysema with multiple doses 
of elastase has some advantages over a single-
dose model, such as increased Lm, a pattern of 
damage similar to that of progressive emphysema 
in humans, and systemic changes10,11,13. The doses 
of elastase used in our study were selected based 
on a previous study by Cruz et al., who reported 
morphological changes in the lung parenchyma, 
with increased Lm and collagen fiber content 
and a decreased amount of elastic fibers in the 
alveolar septa, using 0.1 U of elastase14. In our 
study, however, no statistical difference was 
observed in these parameters when an elastase 
dose of 0.1 U was used. Luthje et al. used an 
elastase dose of 3.3 U/100g (0.66 U per mouse) 
administered once a week for five weeks. The mice 
developed emphysema with a higher Lm (260.7 
μm) than controls (24.7 µm), but also with a higher 
mortality rate due to pneumothorax and pulmonary 
hemorrhage (30%)11. In our study, mean Lm was 
47.5 ± 15.8 μm in the E20 group and no deaths 
were observed, demonstrating the safety of our 
model.
We observed that an increased dose of elastase 
was able to produce emphysema with a reduction 
in the volume fraction occupied by collagen fibers in 
the alveolar septa. The remodeling phase of healing 
involves collagen deposit and begins approximately 
eight days after injury. Initially, type III collagen 
fibers are synthesized, followed by type I collagen 
fibers (more mature and resistant collagen)15. 
Hamakawa et al., in an elastase-induced mouse 
model of emphysema, reported that the ratio of 
type III to type I collagen decreased in the early 
phase (two days after treatment with elastase) and 
then gradually returned to control values (21 days 
after elastase administration)16. Thus, the reduction 
Development of different degrees of emphysema in mice
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in collagen fiber content seven days after the last 
instillation in our study is in accordance with that 
described by Hamakawa et al.16. However, other 
studies have reported an increased amount of 
collagen content in experimental emphysema due 
to the inflammatory process17-19. These differences 
among studies may be attributed to the time points 
used for analysis, as most studies have evaluated 
collagen fiber content at least 14 days after disease 
induction17-19. 
Elastic fiber content also reduced one week 
after the last i.t. instillation of elastase in our 
study, which may be attributed to the release of 
metalloprotease16,20. Since there was no sufficient 
time for lung remodeling, we believe that loss of 
elastin led to enlargement of alveolar spaces, 
supporting the hypothesis that elastolysis promotes 
the development of emphysema. Furthermore, 
Kononov et al. showed that the elastin-collagen 
network exhibited deformation and distortion during 
stretching21. Therefore, in addition to a reduction in 
collagen and elastic fibers, the efficiency of these 
fibers may be compromised, resulting in changes 
in lung mechanics22.
In this study, R increased in mice receiving the 
highest dose of elastase (0.2 U). This mechanical 
change may be attributed to the decrease in 
collagen and elastic content, leading to loss of 
airway tethering, which may limit airway expansion. 
Furthermore, we observed a reduction in TV, MV, 
and PEF. R is inversely proportional to airflow23; 
therefore, since R was higher, TV, VM and PEF 
were consequently lower in the group with greater 
enlargement of alveolar spaces. In humans, R 
values may remain unaltered due to compensation 
resulting from hyperinflation, but this did not occur in 
the E20 group. However, similarly to what occurs in 
human emphysema, there was great involvement of 
the peripheral component23. Ingenito et al. reported 
the same pattern of R in sheep treated with papain, 
suggesting an underlying airway obstruction24. 
No other studies using mice and whole-body 
plethysmography have reported increased R. 
Some studies have employed other evaluation 
methods that use muscle paralysis as an adjunct to 
anesthesia, mainly influencing the assessment of 
airway resistance25-27. Ito et al. showed decreased 
R values with increasing PEEP (higher than 6 
cmH2O), but this was not significant19. In our study, 
we used a PEEP level only sufficient to maintain 
functional residual capacity, thus contributing to 
evaluate solely the effects of emphysema.
In the present study, no differences were 
observed in Cdyn values when compared to those 
of controls. It is known that Cdyn is strongly related 
to elastic tissue (especially collagen fibers)19,28. 
There was no increase in the volume fraction 
occupied by collagen fibers in this study. Thus, the 
stable behavior of Cdyn may be associated with 
the absence of an increasing amount of collagen 
fibers as well as with a balance between areas of 
hyperinflation and collapse.
Perez-Padilla et al., using data from 
large population studies, tested whether pre-
bronchodilator PEF could identify spirometrically 
confirmed post-bronchodilator airflow obstruction. 
Since patients with higher risk for chronic obstructive 
pulmonary disease had lower PEF, the authors 
pointed out the usefulness of PEF measurement as 
an indicator of mortality risk in hospitalized patients, 
in the emergency room screening of exacerbations, 
and for home assessment of patients29. In our study, 
PEF had a significant decrease proportional to the 
increase in the elastase dose, closely resembling 
the behavior of pulmonary emphysema in humans.
The present study has some limitations: (1) all 
analyses were performed one week after the last 
instillation, and therefore there was insufficient time 
for increase in collagen content and elastogenesis, 
and (2) inflammation was not evaluated as to 
whether it correlated with lung function and 
remodeling.
In conclusion, four i.t. instillations of 0.2 U of 
elastase once a week produced an effective and 
safe experimental model of severe pulmonary 
emphysema characterized by changes in 
lung mechanics and histology and elastolysis. 
Additionally, an elastase dose of 0.15 U induced 
a model of emphysema characterized by only 
histological changes. We believe that this study can 
serve as a platform for future research in the field 
of therapy targeting different degrees of pulmonary 
emphysema.
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